Report Detail
EMEA (Europe, Middle East and Africa) Non-alcoholic Steatohepatitis Market Report 2018
- RnM1775718 |
- 21 March, 2018 |
- Global |
- 116 Pages |
- QYResearch |
- Other
In this report, the EMEA Non-alcoholic Steatohepatitis market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.
Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Non-alcoholic Steatohepatitis for these regions, from 2013 to 2025 (forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.
EMEA Non-alcoholic Steatohepatitis market competition by top manufacturers/players, with Non-alcoholic Steatohepatitis sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
AstraZeneca
Arena Pharmaceuticals
GSK
Novo Nordisk
Roche
Vivus
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Immuron
Interceptpharma
Raptor Pharmaceutical
Shire
Tobira Therapeutics
Verva
Viking Therapeutics
On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
Solid
Liquid
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Oral
Parenteral
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
EMEA (Europe, Middle East and Africa) Non-alcoholic Steatohepatitis Market Report 2018
1 Non-alcoholic Steatohepatitis Overview
- 1.1 Product Overview and Scope of Non-alcoholic Steatohepatitis
- 1.2 Classification of Non-alcoholic Steatohepatitis
- 1.2.1 EMEA Non-alcoholic Steatohepatitis Market Size (Sales) Comparison by Type (2013-2025)
- 1.2.2 EMEA Non-alcoholic Steatohepatitis Market Size (Sales) Market Share by Type (Product Category) in 2017
- 1.2.3 Solid
- 1.2.4 Liquid
- 1.3 EMEA Non-alcoholic Steatohepatitis Market by Application/End Users
- 1.3.1 EMEA Non-alcoholic Steatohepatitis Sales (Volume) and Market Share Comparison by Application (2013-2025)
- 1.3.2 Oral
- 1.3.3 Parenteral
- 1.4 EMEA Non-alcoholic Steatohepatitis Market by Region
- 1.4.1 EMEA Non-alcoholic Steatohepatitis Market Size (Value) Comparison by Region (2013-2025)
- 1.4.2 Europe Status and Prospect (2013-2025)
- 1.4.3 Middle East Status and Prospect (2013-2025)
- 1.4.4 Africa Status and Prospect (2013-2025)
- 1.5 EMEA Market Size (Value and Volume) of Non-alcoholic Steatohepatitis (2013-2025)
- 1.5.1 EMEA Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2025)
- 1.5.2 EMEA Non-alcoholic Steatohepatitis Revenue and Growth Rate (2013-2025)
2 EMEA Non-alcoholic Steatohepatitis Competition by Manufacturers/Players/Suppliers, Region, Type and Application
- 2.1 EMEA Non-alcoholic Steatohepatitis Market Competition by Players/Manufacturers
- 2.1.1 EMEA Non-alcoholic Steatohepatitis Sales Volume and Market Share of Major Players (2013-2018)
- 2.1.2 EMEA Non-alcoholic Steatohepatitis Revenue and Share by Players (2013-2018)
- 2.1.3 EMEA Non-alcoholic Steatohepatitis Sale Price by Players (2013-2018)
- 2.2 EMEA Non-alcoholic Steatohepatitis (Volume and Value) by Type/Product Category
- 2.2.1 EMEA Non-alcoholic Steatohepatitis Sales and Market Share by Type (2013-2018)
- 2.2.2 EMEA Non-alcoholic Steatohepatitis Revenue and Market Share by Type (2013-2018)
- 2.2.3 EMEA Non-alcoholic Steatohepatitis Sale Price by Type (2013-2018)
- 2.3 EMEA Non-alcoholic Steatohepatitis (Volume) by Application
- 2.4 EMEA Non-alcoholic Steatohepatitis (Volume and Value) by Region
- 2.4.1 EMEA Non-alcoholic Steatohepatitis Sales and Market Share by Region (2013-2018)
- 2.4.2 EMEA Non-alcoholic Steatohepatitis Revenue and Market Share by Region (2013-2018)
- 2.4.3 EMEA Non-alcoholic Steatohepatitis Sales Price by Region (2013-2018)
3 Europe Non-alcoholic Steatohepatitis (Volume, Value and Sales Price), by Players, Countries, Type and Application
- 3.1 Europe Non-alcoholic Steatohepatitis Sales and Value (2013-2018)
- 3.1.1 Europe Non-alcoholic Steatohepatitis Sales Volume and Growth Rate (2013-2018)
- 3.1.2 Europe Non-alcoholic Steatohepatitis Revenue and Growth Rate (2013-2018)
- 3.2 Europe Non-alcoholic Steatohepatitis Sales and Market Share by Type
- 3.3 Europe Non-alcoholic Steatohepatitis Sales and Market Share by Application
- 3.4 Europe Non-alcoholic Steatohepatitis Sales Volume and Value (Revenue) by Countries
- 3.4.1 Europe Non-alcoholic Steatohepatitis Sales Volume by Countries (2013-2018)
- 3.4.2 Europe Non-alcoholic Steatohepatitis Revenue by Countries (2013-2018)
- 3.4.3 Germany Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
- 3.4.4 France Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
- 3.4.5 UK Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
- 3.4.6 Russia Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
- 3.4.7 Italy Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
- 3.4.8 Benelux Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
4 Middle East Non-alcoholic Steatohepatitis (Volume, Value and Sales Price), by Region, Type and Application
- 4.1 Middle East Non-alcoholic Steatohepatitis Sales and Value (2013-2018)
- 4.1.1 Middle East Non-alcoholic Steatohepatitis Sales Volume and Growth Rate (2013-2018)
- 4.1.2 Middle East Non-alcoholic Steatohepatitis Revenue and Growth Rate (2013-2018)
- 4.2 Middle East Non-alcoholic Steatohepatitis Sales and Market Share by Type
- 4.3 Middle East Non-alcoholic Steatohepatitis Sales and Market Share by Application
- 4.4 Middle East Non-alcoholic Steatohepatitis Sales Volume and Value (Revenue) by Countries
- 4.4.1 Middle East Non-alcoholic Steatohepatitis Sales Volume by Countries (2013-2018)
- 4.4.2 Middle East Non-alcoholic Steatohepatitis Revenue by Countries (2013-2018)
- 4.4.3 Saudi Arabia Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
- 4.4.4 Israel Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
- 4.4.5 UAE Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
- 4.4.6 Iran Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
5 Africa Non-alcoholic Steatohepatitis (Volume, Value and Sales Price) by Players, Countries, Type and Application
- 5.1 Africa Non-alcoholic Steatohepatitis Sales and Value (2013-2018)
- 5.1.1 Africa Non-alcoholic Steatohepatitis Sales Volume and Growth Rate (2013-2018)
- 5.1.2 Africa Non-alcoholic Steatohepatitis Revenue and Growth Rate (2013-2018)
- 5.2 Africa Non-alcoholic Steatohepatitis Sales and Market Share by Type
- 5.3 Africa Non-alcoholic Steatohepatitis Sales and Market Share by Application
- 5.4 Africa Non-alcoholic Steatohepatitis Sales Volume and Value (Revenue) by Countries
- 5.4.1 Africa Non-alcoholic Steatohepatitis Sales Volume by Countries (2013-2018)
- 5.4.2 Africa Non-alcoholic Steatohepatitis Revenue by Countries (2013-2018)
- 5.4.3 South Africa Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
- 5.4.4 Nigeria Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
- 5.4.5 Egypt Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
- 5.4.6 Algeria Non-alcoholic Steatohepatitis Sales and Growth Rate (2013-2018)
6 EMEA Non-alcoholic Steatohepatitis Manufacturers/Players Profiles and Sales Data
- 6.1 AstraZeneca
- 6.1.1 Company Basic Information, Manufacturing Base and Competitors
- 6.1.2 Non-alcoholic Steatohepatitis Product Type, Application and Specification
- 6.1.2.1 Product A
- 6.1.2.2 Product B
- 6.1.3 AstraZeneca Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.1.4 Main Business/Business Overview
- 6.2 Arena Pharmaceuticals
- 6.2.1 Company Basic Information, Manufacturing Base and Competitors
- 6.2.2 Non-alcoholic Steatohepatitis Product Type, Application and Specification
- 6.2.2.1 Product A
- 6.2.2.2 Product B
- 6.2.3 Arena Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.2.4 Main Business/Business Overview
- 6.3 GSK
- 6.3.1 Company Basic Information, Manufacturing Base and Competitors
- 6.3.2 Non-alcoholic Steatohepatitis Product Type, Application and Specification
- 6.3.2.1 Product A
- 6.3.2.2 Product B
- 6.3.3 GSK Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.3.4 Main Business/Business Overview
- 6.4 Novo Nordisk
- 6.4.1 Company Basic Information, Manufacturing Base and Competitors
- 6.4.2 Non-alcoholic Steatohepatitis Product Type, Application and Specification
- 6.4.2.1 Product A
- 6.4.2.2 Product B
- 6.4.3 Novo Nordisk Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.4.4 Main Business/Business Overview
- 6.5 Roche
- 6.5.1 Company Basic Information, Manufacturing Base and Competitors
- 6.5.2 Non-alcoholic Steatohepatitis Product Type, Application and Specification
- 6.5.2.1 Product A
- 6.5.2.2 Product B
- 6.5.3 Roche Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.5.4 Main Business/Business Overview
- 6.6 Vivus
- 6.6.1 Company Basic Information, Manufacturing Base and Competitors
- 6.6.2 Non-alcoholic Steatohepatitis Product Type, Application and Specification
- 6.6.2.1 Product A
- 6.6.2.2 Product B
- 6.6.3 Vivus Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.6.4 Main Business/Business Overview
- 6.7 Arisaph Pharmaceuticals
- 6.7.1 Company Basic Information, Manufacturing Base and Competitors
- 6.7.2 Non-alcoholic Steatohepatitis Product Type, Application and Specification
- 6.7.2.1 Product A
- 6.7.2.2 Product B
- 6.7.3 Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.7.4 Main Business/Business Overview
- 6.8 Cempra Pharmaceuticals
- 6.8.1 Company Basic Information, Manufacturing Base and Competitors
- 6.8.2 Non-alcoholic Steatohepatitis Product Type, Application and Specification
- 6.8.2.1 Product A
- 6.8.2.2 Product B
- 6.8.3 Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.8.4 Main Business/Business Overview
- 6.9 Galectin Therapeutics
- 6.9.1 Company Basic Information, Manufacturing Base and Competitors
- 6.9.2 Non-alcoholic Steatohepatitis Product Type, Application and Specification
- 6.9.2.1 Product A
- 6.9.2.2 Product B
- 6.9.3 Galectin Therapeutics Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.9.4 Main Business/Business Overview
- 6.10 Galmed Pharmaceuticals
- 6.10.1 Company Basic Information, Manufacturing Base and Competitors
- 6.10.2 Non-alcoholic Steatohepatitis Product Type, Application and Specification
- 6.10.2.1 Product A
- 6.10.2.2 Product B
- 6.10.3 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.10.4 Main Business/Business Overview
- 6.11 Genfit
- 6.12 Gilead
- 6.13 Immuron
- 6.14 Interceptpharma
- 6.15 Raptor Pharmaceutical
- 6.16 Shire
- 6.17 Tobira Therapeutics
- 6.18 Verva
- 6.19 Viking Therapeutics
7 Non-alcoholic Steatohepatitis Manufacturing Cost Analysis
- 7.1 Non-alcoholic Steatohepatitis Key Raw Materials Analysis
- 7.1.1 Key Raw Materials
- 7.1.2 Price Trend of Key Raw Materials
- 7.1.3 Key Suppliers of Raw Materials
- 7.1.4 Market Concentration Rate of Raw Materials
- 7.2 Proportion of Manufacturing Cost Structure
- 7.2.1 Raw Materials
- 7.2.2 Labor Cost
- 7.2.3 Manufacturing Expenses
- 7.3 Manufacturing Process Analysis of Non-alcoholic Steatohepatitis
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
- 8.1 Non-alcoholic Steatohepatitis Industrial Chain Analysis
- 8.2 Upstream Raw Materials Sourcing
- 8.3 Raw Materials Sources of Non-alcoholic Steatohepatitis Major Manufacturers in 2017
- 8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
- 9.1 Marketing Channel
- 9.1.1 Direct Marketing
- 9.1.2 Indirect Marketing
- 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
- 9.2.1 Pricing Strategy
- 9.2.2 Brand Strategy
- 9.2.3 Target Client
- 9.3 Distributors/Traders List
10 Market Effect Factors Analysis
- 10.1 Technology Progress/Risk
- 10.1.1 Substitutes Threat
- 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change
11 EMEA Non-alcoholic Steatohepatitis Market Forecast (2018-2025)
- 11.1 EMEA Non-alcoholic Steatohepatitis Sales, Revenue and Price Forecast (2018-2025)
- 11.1.1 EMEA Non-alcoholic Steatohepatitis Sales and Growth Rate Forecast (2018-2025)
- 11.1.2 EMEA Non-alcoholic Steatohepatitis Revenue and Growth Rate Forecast (2018-2025)
- 11.1.3 EMEA Non-alcoholic Steatohepatitis Price and Trend Forecast (2018-2025)
- 11.2 EMEA Non-alcoholic Steatohepatitis Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
- 11.3 Europe Non-alcoholic Steatohepatitis Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
- 11.4 Middle Eastt Non-alcoholic Steatohepatitis Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
- 11.5 Africa Non-alcoholic Steatohepatitis Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
- 11.6 EMEA Non-alcoholic Steatohepatitis Sales Forecast by Type (2018-2025)
- 11.7 EMEA Non-alcoholic Steatohepatitis Sales Forecast by Application (2018-2025)
12 Research Findings and Conclusion
13 Appendix
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
